BridgeBio Oncology (BBOT) CMO uses 1,047 shares to cover RSU tax bill

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. Chief Medical & Development Officer Ben Yong had 1,047 shares of common stock withheld on July 1, 2026 to cover tax obligations tied to vesting restricted stock units. This was an automatic tax-withholding disposition at $7.80 per share, not an open-market trade. After this transaction, Yong directly owned 44,576 shares of BridgeBio Oncology common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ben Yong

Role Chief Med & Dev Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,047	$7.80	$8K

Holdings After Transaction: Common Stock — 44,576 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 1,047 shares Withholding reference price: $7.80 per share Shares owned after transaction: 44,576 shares

3 metrics

Shares withheld for taxes 1,047 shares Common stock withheld to satisfy tax obligations on RSU vesting

Withholding reference price $7.80 per share Value used for tax-withholding disposition of common stock

Shares owned after transaction 44,576 shares Direct common stock holdings following the tax withholding

Key Terms

restricted stock units, tax withholding obligations, Common Stock

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations"

Common Stock financial

"Represents the number of shares of the Issuer's Common Stock withheld"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/06/2026 - 06:00 PM Accepted by SEC EDGAR 07/06/2026 - 06:00 PM Learn about SEC filing dates

FAQ

What did BridgeBio Oncology (BBOT) insider Ben Yong report in this Form 4?

Ben Yong reported a tax-related share withholding, not an open-market trade. The company withheld 1,047 BridgeBio Oncology common shares to satisfy his tax obligations when restricted stock units vested, a routine administrative transaction tied to equity compensation.

How many BridgeBio Oncology (BBOT) shares were withheld for taxes in this filing?

The filing shows 1,047 BridgeBio Oncology common shares were withheld. These shares covered Ben Yong’s tax obligations arising from the vesting of restricted stock units, using a reference price of $7.80 per share to calculate the value of the withholding.

Did Ben Yong sell BridgeBio Oncology (BBOT) shares on the open market?

No, this filing does not show an open-market sale. It reflects an automatic disposition where the issuer withheld shares to cover tax liabilities from RSU vesting, a standard equity compensation mechanism rather than a discretionary buy or sell decision.

How many BridgeBio Oncology (BBOT) shares does Ben Yong hold after this transaction?

After the tax-withholding disposition, Ben Yong directly holds 44,576 BridgeBio Oncology common shares. This total reflects his position following the 1,047 shares withheld by the issuer in connection with the vesting of his restricted stock units.

What was the price used for the BridgeBio Oncology (BBOT) tax-withholding shares?

The filing reports a price of $7.80 per BridgeBio Oncology share for the withholding. This figure is used to determine the value of the 1,047 shares surrendered to satisfy Ben Yong’s tax obligations related to his restricted stock unit vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ben Yong

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Med & Dev Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		F		1,047(1)	D	$7.8	44,576	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

	/s/ Aaron Chan, Attorney-in-Fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)